General
Preferred name
ACETOHEXAMIDE
Synonyms
Acetohexamid ()
Dymelor ()
Gamadiabet ()
NSC-759128 ()
Dimelor ()
33006 ()
Acetohexamida ()
Acetoexamide ()
P&D ID
PD000420
CAS
8054-32-8
968-81-0
Tags
available
drug
Approved by
FDA
First approval
1964
Drug indication
diabetes mellitus
Diabetic complication
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Acetohexamide is an intermediate-acting, first-generation oral sulfonylurea. It lowers blood sugar by stimulating the pancreatic beta cells to secrete insulin and by helping the body use insulin efficiently. Due to its primary action on the pancreatic beta cells, the drug is only effective when there are functional pancreatic beta cells that can produce insulin granules. Acetohexamide has one-third the potency of chlorpropamide, and twice the potency of tolbutamide; however, similar hypoglycemic efficacy occurs with equipotent dosage of sulfonylureas.
DESCRIPTION
A sulfonylurea family drug.
(GtoPdb)
DESCRIPTION
Acetohexamide is a first-generation sulfonylurea agent used in research related to type 2 diabetes; it stimulates the pancreas to secrete insulin.Acetohexamide inhibits ATP-sensitive potassium channels in the ¦Â cells of the pancreas[1].
PRICE
29
DESCRIPTION
Acetohexamide (Acetohexamid) is an intermediate-acting, first-generation sulfonylurea with hypoglycemic activity. It inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (KIR6.2) with Ki values of 22.9 and 14.2 ??M in HEK293 cells transfected with the human receptor and in rat brain, respectively. Acetohexamide is metabolized in the liver to its active metabolite hydroxyhexamide.
DESCRIPTION
Stimulates insulin release
(LOPAC library)
DESCRIPTION
Acetohexamide, a sulfonylurea derivative, is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone. It is a hyopglycemic agent with moderate uricosuric activity. It stimulates the pancreas to secrete insulin and is used as an oral hypoglycemic agent. It was developed by Eli Lilly and Company and has been listed.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Acetohexamide is a first generation sulfonylurea that inhibits sulfonylurea receptor 1 linked to the inwardly rectifying potassium channel. Acetohexamide is used to treat diabetes mellitus type 2; stimulate the pancreas to secrete insulin.
(Enamine Bioactive Compounds)
DESCRIPTION
Acetohexamide (Acetohexamid) is an intermediate-acting, first-generation sulfonylurea with hypoglycemic activity. It inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (KIR6.2) with Ki values of 22.9 and 14.2 μM in HEK293 cells transfected with the human receptor and in rat brain, respectively. Acetohexamide is metabolized in the liver to its active metabolite hydroxyhexamide.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
28
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
LOPAC library
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
37
Molecular Weight
324.11
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
1
cLogP
2.21
TPSA
92.34
Fraction CSP3
0.47
Chiral centers
0.0
Largest ring
6.0
QED
0.83
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Insulin
MOA
Carbonic anhydrase inhibitor
sulfonylurea receptor agonist
ATP channel blocker
Target
Sulfonylurea receptor 1, Kir6.2
NADPH
Potassium Channel
ABCC8, KCNJ1, KCNJ10, KCNJ11
KCNJ1
Indication
diabetes mellitus
ATC
A10BB31
Therapeutic Class
Hypoglycemic Agents
Pathway
Membrane Transporter/Ion Channel
Metabolism
Solubility
DMSO: 39 mg/ml
Source data
